Can Primary Care Scale Any Further? - Summary - MDSpire

Can Primary Care Scale Any Further?

As primary care shortages deepen, health systems are testing AI-supported virtual care to maintain access.

  • By

  • Martha Bebinger, WBUR

  • February 2, 2026

  • 10 min

Share

Objective:

To explore the challenges of primary care access in Massachusetts, including provider shortages and patient experiences, and the role of AI in addressing these issues.

Key Findings:
  • 17% of adults in America lack a primary care physician, with Massachusetts facing a particularly acute shortage that impacts patient care.
  • AI tools like Care Connect can provide timely access to care but raise concerns about missing critical patient details, potentially affecting diagnosis and treatment.
  • Primary care physicians face dissatisfaction due to lower pay compared to specialists, increasing workloads, and a lack of support from health systems.
Interpretation:

While AI tools like Care Connect offer a temporary solution to primary care shortages, they cannot replace the nuanced understanding that comes from long-term patient-physician relationships, which are essential for comprehensive care.

Limitations:
  • AI tools may overlook important medical details and patient context, such as family history or social determinants of health.
  • Concerns about patient privacy and data security with AI usage persist, particularly regarding sensitive health information.
Conclusion:

AI can serve as a short-term bridge to care amid a primary care crisis, but systemic changes, including better support for primary care providers and addressing compensation disparities, are needed to address the root causes of provider shortages.

Original Source(s)

Can Primary Care Scale Any Further?

  • by Martha Bebinger, WBUR

  • February 2, 2026

Related Content

FDA Approves Ensitrelvir to Prevent COVID-19 After Exposure

Phase 3 data showed a 67% reduction in symptomatic infection among exposed household contacts who tested negative at baseline.

FDA Expands Guselkumab Label in PsA

Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.

Retinal Imaging AI May Flag Brain Health Risk

Authors said AI-driven retinal screening still lacks evidence that it improves patient outcomes.